San Antonio’s START earns high praise at national oncology conference
The American Society of Clinical Oncology (ASCO) is conducting its 47th annual conference in Chicago this week and South Texas Accelerated Research Therapeutics (START) has attracted some attention at that gathering.
According to START, a record 28 abstracts, submitted by its physicians and researchers at the ASCO conference, have been selected for publication in the Annual Meeting Proceedings ASCO Conference Book. Abstracts are papers that detail the results of clinical trials.
In addition, Dr. Toshio Shimizu, a START visiting clinical fellow from Osaka, Japan, has been selected as one of 100 ASCO Merit Award winners chosen from around the world. As a result, Shimizu will give a clinical science symposium as a part of the Developmental Therapeutics session, which START officials say is a “very prestigious acknowledgement” by ASCO.
ASCO is a global organization representing physicians who care for cancer patients.
“This is an outstanding accomplishment for any institution involved in clinical cancer research in the world ... ,” says Dr. Anthony Tolcher, director of clinical research for START, about the acknowledgements the San Antonio organization has received in Chicago.
San Antonio-based START, which has centers in San Antonio and Madrid, is opening a new site in Shanghai. It is a world leader in Phase I medical oncology in the cancer arena.